Alexa K. Dowdell

Alexa K. Dowdell

Auto-generated profile, based on publicly available information

Alexa K. Dowdell

Earle A. Chiles Research Institute, Providence Health, Portland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ESEloi Schmauch
Eloi Schmauch
Brian PieningBrian Piening
Brian Piening
Maedeh MohebnasabMaedeh Mohebnasab
Maedeh Mohebnasab
BXBo Xia
Bo Xia
CZChenchen Zhu
Chenchen Zhu
BKBrendan J. Keating
Brendan J. Keating

13 November 2025 in Nature
Verified
Journal Article
Closed access
PDF file
ESEloi Schmauch
Eloi Schmauch
Brian PieningBrian Piening
Brian Piening
ADAlexa K. Dowdell
Alexa K. Dowdell
Maedeh MohebnasabMaedeh Mohebnasab
Maedeh Mohebnasab
SWSimon H. Williams
Simon H. Williams
BKBrendan J. Keating
Brendan J. Keating

3 February 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PDF file
Brian PieningBrian Piening
Brian Piening
ADAlexa K. Dowdell
Alexa K. Dowdell
MZMengqi Zhang
Mengqi Zhang
BLBao-Li Loza
Bao-Li Loza
DWDavid Walls
David Walls
BKBrendan J. Keating
Brendan J. Keating

29 April 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
TBTiffany C Blair
Tiffany C Blair
SBShelly Bambina
Shelly Bambina
GKGwen F Kramer
Gwen F Kramer
ADAlexa K Dowdell
Alexa K Dowdell
AAAlejandro F Alice
Alejandro F Alice
MGMichael J Gough
Michael J Gough
Radiation therapy generates extensive cancer cell death capable of promoting tumor-specific immunity. Within the tumor, conventional dendritic cells (cDCs) are known to carry tumor-associated antigens to the draining lymph node (TdLN) where they initiate T-cell priming. How radiation influences cDC migration is poorly understood. Here, we show that immunological efficacy of radiation therapy is dependent on cDC migration in radioimmunogenic tumors. Using photoconvertible mice, we demonstrate that radiation impairs cDC migration to the TdLN in poorly radioimmunogenic tumors. Comparative transcriptional analysis revealed that cDCs in radioimmunogenic tumors express genes associated with activation of endogenous adjuvant signaling pathways when compared with poorly radioimmunogenic tumors. Moreover, an exogenous adjuvant combined with radiation increased the number of migrating cDCs in these poorly radioimmunogenic tumors. Taken together, our data demonstrate that cDC migration play a critical role in the response to radiation therapy.

1 November 2024 in JCO Oncology Practice
Verified
Journal Article
Open access
ADAlexa K. Dowdell
Alexa K. Dowdell
RMRyan C. Meng
Ryan C. Meng
AVAnn Vita
Ann Vita
BBBela Bapat
Bela Bapat
DHDouglas Hanes
Douglas Hanes
Brian PieningBrian Piening
Brian Piening
PURPOSE: Precision therapies and immunotherapies have revolutionized cancer care, with novel genomic biomarker-associated therapies being introduced into clinical practice rapidly, resulting in notable gains in patient survival. Despite this, there is significant variability in the utilization of tumor molecular profiling that spans the timing of test ordering, comprehensiveness of gene panels, and clinical decision support through therapy and trial recommendations. METHODS: To standardize testing, we designed a pathologist-directed test ordering system at the time of diagnosis using a 523-gene DNA/RNA hybrid comprehensive genomic profiling (CGP) panel and extensive clinical decision support tools. To comprehensively characterize the clinical impact of this protocol, we developed a novel natural language processing (NLP)–based approach to extract clinical features from physician chart notes. We assessed test actionability rates, therapy choice, and outcomes across a set of 3,216 patients with advanced cancer. RESULTS: We observed 49% of patients had at least one actionable genomic biomarker-driven–approved and/or guideline-recommended targeted or immunotherapy (IO) and 53% of patients would have been eligible for a precision therapy clinical trial from three large basket trials. When assessing CGP versus an in silico 50-gene panel, 67% of tumors compared with 33% harbored actionable alterations including clinical trials. Among patients with 6 months or more of follow-up, over 52% received a targeted therapy (TT) or IO, versus 32% who received conventional chemotherapy alone. Furthermore, patients receiving TT had significantly improved overall survival compared with patients receiving chemotherapy alone ( P < .001). CONCLUSION: Overall, these data represent a major shift in standard clinical practice toward molecularly guided treatments (targeted and immunotherapies) over conventional systemic chemotherapy. As guidelines continue to evolve and more precision therapeutics gain approval, we expect this gap to continue to widen.

25 July 2024 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
RMR. Meng
R. Meng
ADA.K. Dowdell
A.K. Dowdell
AVA. Vita
A. Vita
DHDouglas Hanes
Douglas Hanes
BBB. Bapat
B. Bapat
Brian PieningBrian Piening
Brian Piening
New breakthroughs in precision therapies are transforming cancer care for patients with advanced non-small-cell lung cancer (NSCLC). To this effect, comprehensive genomic profiling (CGP) has emerged as a streamlined workflow to test for all relevant tumor biomarkers within a single assay. Despite this, there are still significant gaps in access to CGP testing, with many patients only tested for a subset of biomarkers or not tested at all. We assessed the clinical impact of wide deployment of an in-house CGP assay at a large health care system in the United States by analyzing a cohort of advanced-stage NSCLC patients who received CGP testing and a retrospective cohort that was tested with a prior-generation 50-gene assay (small panel). Seventy-seven percent of CGP-tested NSCLC patients had one or more tumor biomarkers that were actionable for a precision therapy compared to 63% of small panel-tested patients. CGP-tested patients with an actionable biomarker received appropriate precision therapies at a higher rate than small panel-tested patients (64% versus 50%, P < 0.001), and there were marked improvements in survival outcomes for patients tested with CGP [median overall survival (OS) 15.7 months versus 7 months, P < 0.0001]. These data demonstrate clear precision therapy selection and patient OS benefits from universal access to CGP testing. Despite this, not all patients with an actionable biomarker received a precision therapy, suggesting that there are still gaps between access to CGP testing and access to precision therapies.